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patient years at risk, hospital days and costs of hospitalization
per patient per year per modality, annual growth rate of end
stage renal disease (ESRD), and years to reach new modality
shares. The study used data from the monthly clinical report
(MCR) for the year 2005 in the network of renal clinics of Renal
Therapy Services (RTS) Colombia. The entire hospitalization
events were included. Cost data were obtained from a renal unit
from the RTS network and imputed on a daily basis. RESULTS:
A total of 7441 patients were under RRT in the RTS network in
Colombia in 2005. 57.2% were on HD and 42.8% on PD. For
patients on PD, 79.5% were on continuous ambulatory PD
(CAPD) and 20.5% on automated PD (APD). The average daily
costs of a hospital admission per patient in 2006 US dollars were
estimated to be $334 for HD, $175 for CAPD, and $206 for
APD. The annual growth rate of ESRD was estimated to be 8%.
A hypothesized shift of 5% of the patients in treatment modal-
ity from HD to PD in a ﬁve-year period represented a cumu-
lative net savings of $2,332,423 in total hospital costs. 
CONCLUSION: This simulation model analysis indicates that
an increased use of PD results in substantial savings in the hos-
pital costs of patients in RRT, and in a signiﬁcant impact on the
budget of the health care system.
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OBJECTIVES: Brazil has a very developed renal transplantation
program, ﬁnanced entirely by the government. Tacrolimus is one
of the most used drugs to prevent graft rejection. A clinical study,
presented during the 2006 Mexican National Transplantation
Congress, raised some concerns about non-interchangeable
generic substitution of tacrolimus. We developed a decision-
making model that will allow the user to weigh risks and 
beneﬁts of substituting tacrolimus by a generic formulation.
METHODS: We developed a Markov model, using Monte 
Carlo simulation, describing the clinical history of post-renal
transplantation patients over a 5-year period. The model esti-
mates clinical outcomes, rejection episodes, graft loss, patients
returning to dialysis, re-transplantation, number of deaths, 
costs and cost-effectiveness (in terms of rejections avoided) 
of immunosuppressive treatment with original versus generic
tacrolimus. Transition probabilities were derived from the US
Renal Data System, the Brazilian renal transplantation program,
the above-mentioned Mexican study and international medical
literature. Local management of each health state was based on
a Delphi panel and government program costs were applied. A
3% annual discount rate was used. Sensitivity analyses were per-
formed for key parameters. RESULTS: Over a 5-year horizon
and simulating 10,000 patients in the base case scenario, origi-
nal versus generic tacrolimus generated fewer rejections (1005),
fewer patients needing dialysis (609), fewer re-transplantations
(114), fewer deaths (164), and was thus able to reduce (avoid)
total costs by 2%. A cost-effectiveness curve was derived that
illustrates the trade-off between key parameters, such as rejec-
tion rate and treatment cost. CONCLUSION: Lower treatment
costs may be offset by the impact of clinical outcomes if the
generic formulation of tacrolimus were not therapeutically
equivalent to the original. We developed a decision-analytic
model resulting in cost-effectiveness curves that illustrate the
trade-off between these risks and beneﬁts, and will enable an
informed decision-making process regarding generic substitution
of tacrolimus.
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OBJECTIVES: Icodextrin-based solutions have potential clinical
advantages over glucose-based solutions in ﬂuid and metabolic
management of diabetic end state renal disease (ESRD) patients
undergoing peritoneal dialysis (PD). The cost-effectiveness (CE)
of icodextrin-based solutions compared to glucose-based solu-
tions is not known. The purpose of the present study is to esti-
mate CE of icodextrin-based solution for peritoneal dialysis in
diabetic ESRD patients with high average and high peritoneal
transport. METHODS: A decision analytic model was developed
to estimate cost per life year gained of icodextrin-based solu-
tions. Clinical (improvement in peritoneal ultraﬁltration, reduc-
tion of extracellular ﬂuid volume, metabolic, blood pressure
control, edema, therapy related complications, and mortality)
and resource utilization (all-cause hospital admissions and
lengths of stay) data were obtained from a 12 month, multicen-
ter, open-label, randomized, clinical trial conducted in the
Mexican Institute of Social Security (IMSS) in Mexico City
where patients were assigned in one of two groups, dextrose
(GLU, n = 29) or icodextrin (ICO = 30). Cost data, expressed in
2006 US dollar, were obtained from ﬁnancial information data-
base in IMSS. Costs related to adverse events, drugs, hospital-
izations, medical care, intensive care unit and surgery were
included. Univariate and probabilistic sensitivity analyses were
performed using a Monte Carlo simulation method. RESULTS:
Clinical data indicated that icodextrin-based solution was a sig-
niﬁcant aid for the management of this population. Patients in
ICO group had lower hospital length of stay (on average 3 day)
compared to GLU group. The total per patient per year cost of
ICO group was $13,953, while that for GLU group was
$16,788. Expected cost-effectiveness ratios were $14,209 per life
year gained and $17,716 per life year gained for ICO and GLU,
respectively (p < 0.0001). ICO group was also shown to be dom-
inant in 100% of cases. CONCLUSION: Icodextrin-based solu-
tion was cost-effective in treating diabetic ESRD patients 
with high average and high peritoneal transport undergoing PD
treatment.
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OBJECTIVES: Secondary hyperparathyroidism (SHPT) can lead
to signiﬁcant morbidity, mortality, & health care resource uti-
lization in chronic kidney disease (CKD) Stage 5 patients receiv-
ing hemodialysis. The objective of this study was to determine if
predialysis patients with SHPT experience similar clinical and
